10 results about "Streptococcus infection" patented technology

The invention relates to a fusion protein, an immunogenic composition and a recombinant degenerate vaccine for preventing and treating infection of various pathogenic streptococci, as well as a molecular architecture design, application and the like. According to the invention, three immune antigens, namely an elongation factor Tu (Tuf), a molecular chaperone DnaK and an elongation factor G (fusA), are screened, and it is proved that fusion protein molecules of the three antigens can significantly inhibit tissue lesions caused by infection of different serotypes and different types of streptococci, have good immunogenicity, play roles in immune protection and effective prevention and treatment, and have good application prospects. The bacillus subtilis has the characteristics of broad-spectrum and high-efficiency prevention of streptococcus bacterial infection, and has a wide application prospect.

The present invention relates to a fusion protein, immunogenic composition, recombinant vaccine, and molecular architecture design and application, etc., for the prevention of Streptococcus Pneumoniae infection. The present invention starts from the protein molecular tertiary structures of ply and PhtD, and via creatively screening, the C-terminal domain of ply protein and the N-terminal domain of phtD protein are finally selected to construct a fusion protein, and the elements such as Fc domain and STABILON are further added. The fusion protein molecule of the present invention can weaken tissue lesions caused by Streptococcus Pneumoniae infection, has good immunogenicity, has an effective preventive and immunoprotective effect, and efficiently prevents Streptococcus Pneumoniae infection. The immunogenic composition, fusion protein, and recombinant vaccine for preventing Streptococcus Pneumoniae infection of the present invention have broad application prospects.

The invention discloses application of elaifolin in preparation of a medicine for resisting streptococcus suis, and belongs to the field of microbial infectious diseases and medicines. The invention finds that the elaifolin can efficiently inhibit and kill a plurality of serotype streptococcus suis and obviously inhibit or remove biological membranes of the streptococcus suis. The elaifolin can be applied to preparation of anti-streptococcus suis bacteriostasis and sterilization medicines, medicines for treating streptococcus suis infection and medicines for inhibiting or removing streptococcus suis biological membranes. According to the application disclosed by the invention, new medicinal value of the elaifolin is found, and a new prevention and treatment strategy is provided for streptococcus suis drug resistance and biofilm infection; the elaifolin can efficiently act on the multi-drug-resistant streptococcus suis, and a new direction is provided for relieving antibiotic drug resistance crisis.

The application relates to application of lactococcus lactis in a composition for inhibiting streptococcus pyogenes and angina streptococcus and a product, and belongs to the field of microbial technology. The technical problem to be solved is to provide application of lactococcus lactis in preparation of a composition for inhibiting streptococcus pyogenes and angina streptococcus or treating tumors, and the technical solution points are that the lactococcus lactis is applied in preparation of the composition for inhibiting streptococcus pyogenes and angina streptococcus. The lactococcus lactis OA56 of the application can efficiently inhibit streptococcus pyogenes and angina streptococcus, has low ability of forming a biological membrane, shows strong adhesion to oral epithelial cells and hydroxyapatite, can effectively relieve clinical symptoms caused by streptococcus pyogenes infection, reduce inflammation reaction of gastric epithelial cells induced by angina streptococcus infection, and can treat or assist in treating angina streptococcus related tumors.

An immunogenic complex comprising i) an amino acid sequence of an N-terminal region of a group B Streptococcus surface protein selected from the group consisting of: a first amino acid sequence having at least 98%, such as 99%, identity to SEQ ID NO: 16 and a length of 172 amino acids to 178 amino acids; a second amino acid sequence having at least 98%, such as 99%, identity to SEQ ID NO: 18 and a length of 167 amino acids to 173 amino acids; and a third amino acid sequence consisting of SEQ ID NO: 20; and ii) a capsular polysaccharide, is provided. An immunogenic product, a vaccine, and the immunogenic complex, the immunogenic product or the vaccine for use in a method of preventing or treating a group B Streptococcus infection, are also provided.

The application relates to the fields of molecular biology and fish breeding, in particular to application of a specific target sgRNA for knocking out an NSD2 gene in construction of a streptococcus-resistant tilapia strain, and discloses a method for knocking out the NSD2 gene in the tilapia based on CRISPR / Cas9 technology and constructing the streptococcus-resistant tilapia strain. The tilapia with the knocked-out NSD2 gene has stronger resistance to streptococcus infection, and the survival rate is obviously improved when the tilapia is infected with streptococcus.

The application belongs to the technical field of genetic engineering, and provides an oahs gene deletion strain and application thereof in prevention of Streptococcus suis type 2 infection.The oahs gene deletion strain, namely SC19-ΔOAHS, has very low virulence and is basically non-toxic.The mutant strain has basically no infection damage to mice when the mice are immunized with a large dose of live bacteria, and the antibody titer in the mice is obviously increased with the aid of an adjuvant, so that the immunoprotection can be successfully established.The immunoprotection established after a normal immunization procedure can help the mice effectively resist the infection of Streptococcus suis type 2, reduce the mortality and bacterial colonization in the body.The preparation method of SC19-ΔOAHS is simple, and the strain can be prepared in a short period of time, is simple to culture, and does not need other complex treatment as a vaccine, and can be used after washing and mixing with an adjuvant.SC19-ΔOAHS has the potential to be used as a live bacteria vaccine against Streptococcus suis infection in pigs.

The invention relates to the technical field of aquaculture, in particular to nile tilapia hepcidin as well as a preparation method and application thereof and a bacteriostatic agent. The amino acid sequence of the nile tilapia hepcidin is as shown in SEQ ID No.1, and the nile tilapia hepcidin can inhibit streptococcus agalactiae and / or aeromonas hydrophila. According to the method, the nile tilapia hepcidin can be simply, conveniently and efficiently purified, in-vitro experiments prove that the nile tilapia hepcidin can inhibit proliferation of pathogenic bacteria, and in-vivo experiment research results prove that the hepcidin can remarkably improve the streptococcus infection resistance of tilapia.

The invention relates to the field of molecular biology and fish breeding, in particular to application of a specific target sgRNA for knocking out an NSD2 gene in the aspect of constructing an anti-streptococcus tilapia strain, and further discloses a method for knocking out the NSD2 gene in tilapia and constructing the anti-streptococcus tilapia strain based on a CRISPR / Cas9 technology. Compared with the wild tilapia with the NSD2 gene knocked out, the tilapia with the NSD2 gene knocked out has higher capability of resisting streptococcus infection bacteria, and the survival rate is obviously improved when the tilapia is infected with streptococcus.

The present invention discloses a porcine monoclonal antibody against the SzM protein of Streptococcus zooepidemicus and its application. Using genetic recombination technology, a murine monoclonal antibody with excellent efficacy in preventing or treating S. zooepidemicus infection was porcine-derived. The resulting chimeric antibody replaces the constant region of the murine antibody with that of the porcine antibody, thus avoiding the common inability of murine antibodies to effectively activate complement and Fc receptor-related immune effects in pigs. This antibody is highly effective in treating S. zooepidemicus infection in pigs, providing a new and effective biological product for the clinical prevention and treatment of S. zooepidemicus infection in pigs.